- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02161393
Physical Activity Versus Pulmonary Rehabilitation in COPD (LIVELY)
PhysicaL actIvity interVention vErsus puLmonarY Rehabilitation in COPD: The LIVELY COPD Project.
The primary aim of this study is to assess the feasibility of conducting a trial to investigate the effectiveness of a physical activity intervention (physical activity consultation and a pedometer-based walking programme) versus pulmonary rehabilitation in improving physical activity in COPD.
Objectives are:
(i) to assess the feasibility (patient recruitment, adherence, drop-outs and adverse events) of delivering a physical activity intervention in the COPD patient population versus pulmonary rehabilitation; (ii) to explore users perceptions relating to satisfaction and benefits of a physical activity intervention versus pulmonary rehabilitation; (iii) to investigate between and within group change in physical activity, exercise capacity, quality of life, self-efficacy and changes in the transtheoretical model with the physical activity intervention versus pulmonary rehabilitation; and (iv) to examine the cost of delivering a physical activity intervention versus pulmonary rehabilitation for patients with COPD.
The hypothesis for this study is that it will be feasible to conduct a trial that will investigate the effectiveness of a physical activity intervention (physical activity consultation and a pedometer-based walking programme) compared to pulmonary rehabilitation for improving physical activity in COPD. The study will provide important information about interventions designed to promote and maintain physical activity, improve patient outcomes and increase patients' choice relating to exercise and physical activity interventions. It will provide a rationale and data for an adequately powered clinical trial evaluating the effects of a physical activity intervention.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A survey of pulmonary rehabilitation programmes mirrored the results of other UK studies and highlighted that there are not enough programmes available; currently in the UK less than 1.5% of patients with COPD receive pulmonary rehabilitation per year. Only a proportion of patients are targeted i.e. those with moderate to severe disease. The majority of programmes are outpatient-based and are supervised by clinicians. This structured and supervised format of pulmonary rehabilitation does not meet the needs of all patients with high numbers of dropouts and non-adherence; yet alternative options for increasing physical activity for patients with COPD currently do not seem to be offered.
A home-based pedometer-driven walking intervention offers an alternative method of delivering physical activity training that could be provided to larger numbers of patients, at a lower cost and with flexibility around life commitments. It would also provide patients with more choice when deciding whether to participate in exercise or physical activity.
To date no study has compared a home-based walking intervention to structured, supervised pulmonary rehabilitation or the patient preferences or cost of the two programmes. For this reason, there is a need to compare a home-based-walking intervention to the standard method of providing patients with physical activity training, i.e. pulmonary rehabilitation. Therefore this study is essential as it will assess the feasibility of conducting a trial to investigate the efficacy of a physical activity intervention (physical activity consultation and a pedometer-based walking programme) versus pulmonary rehabilitation in improving physical activity in COPD.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Enniskillen, United Kingdom
- Western Health and Social Care Trust
-
-
Co Antrim
-
Belfast, Co Antrim, United Kingdom, BT9 7AB
- Belfast Health and Social Care Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The Patient must be referred to pulmonary rehabilitation.
- The Patient must have a Primary diagnosis of COPD
- The Patient must have a good understanding of written English (as reported by the individual patient)
- The Patient must be in a stable phase (not on antibiotics at the time of assessment with the ISWT), and deemed clinically stable by the clinical pulmonary rehabilitation team.
Exclusion Criteria:
- The inability to safely take part in a walking programme or pulmonary rehabilitation (e.g. unstable angina, neurological, spinal or skeletal dysfunction affecting ability to exercise)
- The inability to comprehend or follow instructions (e.g. dementia).
- Clinically unstable (Pulmonary exacerbation or any change in symptoms and medication in the last 4 weeks)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Physical Activity Intervention
12 week home-based walking programme consisting of weekly physical activity consultations and a pedometer-driven walking programme
|
The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations.
Pedometers will be used to set weekly step goals and motivate patients.
Patients will wear the pedometer for 7 days and will record their daily steps in a step diary.
At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant.
Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week.
The walking programme will be tailored to the individual and progressed on a weekly basis.
|
Active Comparator: Pulmonary Rehabilitation Programme
6-week supervised outpatient programme consisting of twice-weekly exercise sessions and once-weekly education sessions.
|
This will be a 6-week supervised outpatient programme.
The exercise component will last for one hour and be delivered twice weekly.
It will consist of cardiovascular exercises and lower and upper body strengthening exercises.
Education sessions will be delivered once weekly.
Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in physical activity will be assessed using step counts recorded with an Actigraph activity monitor.
Time Frame: Baseline and at 6-weeks for PR group and 12-weeks for PA group
|
The activity monitor is worn for 7 consecutive full days prior to the intervention, and 7 full days immediately after the intervention.
|
Baseline and at 6-weeks for PR group and 12-weeks for PA group
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in time spent in physical activity and in sitting using the International Physical Activity Questionnaire
Time Frame: Baseline and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
Baseline and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
|
Change from baseline in exercise Capacity using the Incremental Shuttle Walk Test
Time Frame: Baseline, and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
Baseline, and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
|
Change from baseline in Quality of Life using the EuroQOL-5D
Time Frame: Baseline, and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
Baseline, and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
|
Change from baseline in Quality of Life using the COPD Assessment Test
Time Frame: Baseline, and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
Baseline, and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
|
Stage of change in terms of physical activity using the Stages of Change Questionnaire
Time Frame: Baseline, and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
The Stages of Change Questionnaire is the temporal part of the transtheoretical model.
It will be used to determine the current stage of change the participant is at in terms of their physical activity behaviour.
|
Baseline, and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
Confidence to undertake physical activity using Marcus's Self-Efficacy Questionnaire
Time Frame: Baseline and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
Marcus's Self-Efficacy Questionnaire is a component of the transtheoretical model which will provide more detailed information on each individual's confidence to undertake physical activity in different situations.
|
Baseline and at 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
Patients' perceptions of both interventions will be obtained via semi-structured interviews.
Time Frame: At 6-weeks for PR group and 12-weeks for PA group
|
Information will be collected with regards patient satisfaction with their exercise/activity, information regarding ease of execution, safety and tolerability of the programmes and the outcome measures, views about continuing exercise and suggestions for improving the programmes.
|
At 6-weeks for PR group and 12-weeks for PA group
|
Feasibility of the interventions
Time Frame: End of study
|
For both interventions information will be collected on recruitment and retention, dropouts, adherence and adverse events which will be necessary to establish feasibility.
|
End of study
|
Global Rating of Change Questionnaire
Time Frame: At 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
This is a numerical rating scale about their patient's perception of any change in their physical activity
|
At 6-weeks for PR group and 12-weeks for PA group, and follow up at 18 (PR group) and 24 (PA group) weeks post randomisation
|
Physical activity will be assessed using step counts recorded with an Actigraph activity monitor.
Time Frame: At 18 (PR group) and 24 (PA group) weeks post randomisation
|
At 18 (PR group) and 24 (PA group) weeks post randomisation
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WT12/20
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
-
Elpen Pharmaceutical Co. Inc.Completed
Clinical Trials on Physical Activity Intervention
-
Brown UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
University of ConnecticutNational Institutes of Health (NIH); National Center for Complementary and...RecruitingChronic Low Back PainUnited States
-
Institut Català d'OncologiaUnknownRecurrence | Breast NeoplasmsSpain
-
Centre Leon BerardNational Cancer Institute, FranceNot yet recruitingMetastatic Testicular CancerFrance
-
University of California, DavisActive, not recruitingBehavior, HealthUnited States
-
Jamie JacksonNational Heart, Lung, and Blood Institute (NHLBI)CompletedPhysical Activity | Cardiovascular Disease OtherUnited States
-
Brown UniversityNational Cancer Institute (NCI)Not yet recruiting
-
Jamie JacksonCompletedPhysical Activity | Cardiovascular Disease OtherUnited States
-
The Miriam HospitalUnknownStroke | Sedentary Lifestyle | Ischemic Attack, Transient | ExerciseUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownObesity | Overweight | Learning DisabilityIsrael